Entera Bio (ENTX) FCF Margin (2021 - 2025)

Entera Bio's (ENTX) quarterly FCF Margin came in at 3361.9% in Q1 2025, down 87.53% on a QoQ basis from 1792.68% in Q4 2024.

Entera Bio (ENTX) FCF Margin (2021 - 2025) Analysis & Trends

Entera Bio (ENTX) has 4 years of FCF Margin data on file, last reported at 3361.9% in Q1 2025.

Quarterly FCF Margin changed N/A year-over-year to 3361.9% in Q1 2025, while the trailing twelve-month figure through Dec 2025 was 17802.38% (down 1403387.0% YoY) and the FY2025 annual result came in at 17802.38%, down 1403387.0% from the prior year.
FCF Margin slipped to 3361.9% in Q1 2025, from 1792.68% in the prior quarter.
In the past five years, FCF Margin ranged from a high of 1478.34% in Q1 2021 to a low of 35887.5% in Q3 2022.
A 4-year average of 6909.31% and a median of 2852.01% in 2024 frame the typical range for FCF Margin.
The widest YoY moves for FCF Margin: up 452231 bps in 2022, down 3437607 bps in 2022.
Tracing ENTX's FCF Margin over 4 years: stood at 1528.48% in 2021, then plunged by 841 bps to 14385.71% in 2022, then surged by 88 bps to 1792.68% in 2024, then slumped by 88 bps to 3361.9% in 2025.
The last three FCF Margin figures came in at 3361.9% (Q1 2025), 1792.68% (Q4 2024), and 5128.57% (Q3 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	30.39%
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	13.35%
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-388.28%
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	25.68%
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	22.62%
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	41.07%
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-22.35%
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	70.82%
10	Entera Bio	161.44 Mn	150.13 Mn	-	-

Download Data